Chimeric antigen receptor T cell therapeutics - Shanghai Unicar-Therapy Bio-medicine Technology

Drug Profile

Chimeric antigen receptor T cell therapeutics - Shanghai Unicar-Therapy Bio-medicine Technology

Alternative Names: meso-CAR

Latest Information Update: 31 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shanghai Unicar-Therapy Bio-medicine Technology
  • Developer Shanghai Unicar-Therapy Bio-medicine Technology; Soochow University; The Third Xiangya Hospital of Central South University
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Non-Hodgkin's lymphoma
  • Phase I Acute lymphoblastic leukaemia; Multiple myeloma; Pancreatic cancer

Most Recent Events

  • 12 Sep 2017 Shanghai Unicar-Therapy Bio-medicine Technology plans a phase I/II trial for Acute lymphoblastic leukaemia (Refractory metastatic disease, In children, In adolescents, In adults) (NCT03275493)
  • 15 Jun 2017 Phase-I clinical trials in Pancreatic cancer (Metastatic disease, Second-line therapy or greater, Inoperable/Unresectable) in China (IV) (NCT03267173)
  • 01 Jun 2017 Phase-II clinical trials in Non-Hodgkin's lymphoma (In children, In adolescents, In adults, Second-line therapy or greater) in China (Infusion) (NCT03196830)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top